


CONFUSED ABOUT CANNABIS?

A Look at the Evidence for Medical Marijuana in Pets

CANNABIS: GOD'S GIFT OR DEVIL'S WEED?

Genesis 1:12


- and the earth brought forth grass, and herb yielding seed ... and God saw that it was good.









CANNABIS IS BAD





CANNABIS IS BAD



Marijuana is probably the most dangerous drug in America today.

— Ronald Reagan —

AZ QUOTES

CANNABIS IS GOOD





CANNABIS IS GOOD




"Cannabis is the single most versatile herbal remedy, and the most useful plant on Earth. No other single plant contains as wide a range of medically active herbal constituents."



CANNABIS IS BAD (FOR PETS)



CANNABIS IS GOOD (FOR PETS)



CANNABIS IS GOOD (FOR PETS)

"Quite a few studies that show many benefits."

- Anxiety
- Arthritis
- Epilepsy
- Diabetes
- Nausea and Vomiting
- Skin Issues
- Cognitive Dysfunction
- Cancer

Hemp Benefits for Dogs



https://www.natural-dog-health-remedies.com/ hemp-benefits.html



- Genus Cannabis
 - Possible species or subspecies C. sativa and C. indicus
 - Hundreds of chemical compounds
 - Cannabinoids
 - Terpenoids
 - Flavanoids
 - Others



- Key compounds
 - Tetrahydrocannabinol (THC)
 - Cannabidiol (CBD)

$$H_3C$$
 H_2C
 H_3
 H_3C
 H



Physiologic effects of cannabinoids

- Endocannabinoid receptors in the brain, also in the GI tract, liver, skeletal muscle
- Other receptors (serotonergic, vanniloid, adenosine)
- Antioxidant effects



Physiologic effects of cannabinoids

 Wide range of effects on mood, appetite, emesis, pain, inflammation, immune function, nerve function




Physiologic effects vary with

- Strain of Cannabis and relative levels of various compounds
- Route of administration
- Form (herbal, extracts, resin, medicinal products)


MEDICINAL USE OF CANNABIS

- Long history of medicinal use
- Currently few approved Cannabis-based products
 - dronabinol-synthetic THC (nausea, inappetence)
 - nabilone- synthetic THC analog (nausea, pain)
- In development or approved outside the US
 - Sativex-THC/CBD extract (MS)
 - Epidiolex- CBD extract (epilepsy)



MEDICINAL USE OF CANNABIS

• Variable state laws regarding medical and nonmedical use in humans.






MEDICINAL USE OF CANNABIS

- No FDA approved products for veterinary use
- Off-label use of dronabinol and nabilone not specifically prohibited
- Both THC-containing and CBD-containing products are illegal under federal law
- No state laws specifically allow veterinary use of Cannabis-derived products
- The FDA specifically excludes products with THC or CBD from looser regulation for dietary supplements



- Clinical trials in veterinary patients
- Clinical trials in humans
- Laboratory research in relevant species
- Other laboratory evidence (rats, in vitro, etc.)
- Anecdotal experience



Clinical trials in veterinary patients- none (yet)

- Clinical trials in veterinary patients- coming soon!
 - Pending studies
 - Upenn, Cornell, CSU, Auburn





The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

- Clinical trials in humans
 - 2016 review
 - Evaluated many therapeutic indications and potential risks
 - Graded the strength of evidence
 - Identified limitations in //
 evidence and strategies for improvement

Evidence Levels

- Conclusive
 - Strong evidence from RCTs
 - Many supportive findings and no credible opposing findings
 - Negligible limitations to evidence
- Substantial
 - Strong evidence
 - Several supportive findings and minimal opposing findings
 - Minor limitations to evidence

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

- Evidence Levels
 - Moderate Evidence
 - Some good-to-fair quality evidence
 - Very few opposing findings
 - Cannot confidently rule out bias/error
 - Limited Evidence
 - No or Insufficient Evidence

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

There is conclusive or substantial evidence that cannabis or cannabinoids are effective:

- For the treatment of chronic pain in adults
- As antiemetics in the treatment of chemotherapy-induced nausea and vomiting
- For improving patient-reported multiple sclerosis spasticity symptoms

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

There is moderate evidence that cannabis or cannabinoids are effective:

 Improving short-term sleep outcomes in individuals with sleep disturbance associated with obstructive sleep apnea syndrome, fibromyalgia, chronic pain, and multiple sclerosis

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

For everything else:

- Limited evidence for or against efficacy
- Insufficient evidence to form a conclusion

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

What About...

- Glaucoma
 - Short-term effects in lab and uncontrolled studies
 - No moderate or better evidence
- Epilepsy
 - Few recent studies of CBD (after 2016 review)
 - Reduction in Sz in patients with drug resistant epilepsy
 - Common adverse effects (GI, neuro)

The Health Effects of Cannabis and Cannabinoids


THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

What about Risks and Harms?



The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

Risks and Harms (moderate or better evidence)

- NOT associated with lung or head and neck cancers
- Worsening of respiratory disease symptoms/bronchitis (smoking)
- Increased risk of motor vehicle accidents

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

Risks and Harms (moderate or better evidence)

- Accidental overdose in children where legalized (and dogs)
- Lower birth weight if used while pregnant
- Dose-dependent increase in development of schizophrenia and psychoses
- Other psychological symptoms (bipolar, depression, suicidal ideation, etc.)

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

Risks and Harms (moderate or better evidence)

Development of substance abuse

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

Risks and Harms Seen in RCTs

- Vomiting/Diarrhea/Inappetance
- Sedation/Fatigue
- Drug Interactions? (cytochrome enzyme inhibitor)
- Infections?
- Allergies

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

Risks and Benefits Relevant to Veterinary Patients

- Chronic pain
- Nausea and vomiting
- Accidental overdose
- Allergies
- Use in pregnancy?
- Psychological risks?

The Health Effects of Cannabis and Cannabinoids

THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH

Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda

Board on Population Health and Public Health Practice

Health and Medicine Division

Laboratory Studies in Relevant Species

- Few studies, mostly from 1950s-1970s
- Pharmacokinetic/pharmacologic studies
- Toxicity studies
- IV THC or inhaled marijuana, some oral exposure
- No info directly evaluating therapeutic uses



Laboratory Studies in Relevant Species

- Confirm cannabinoid receptors present homologous to other species, dogs have more in the brain than humans
- Evidence of toxicity similar to clinical case reports (neuro, GI, reproductive)



Laboratory Studies in Relevant Species

Variable evidence for bioavailability

Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos. 1988 May-Jun;16(3):469-72.

In three of the six dogs studied, CBD could not be detected in the plasma after oral administration. In the other three, the oral bioavailability ranged from 13 to 19%. The results of this study show that CBD is barely absorbed after oral administration to dogs. This low bioavailability may be due to a first pass effect.



ASSESSMENT OF SAFETY, TOXICITY, AND PHARMA-COKINETICS OF CANNABIDIOL IN HEALTHY DOGS. L. Bartner¹, L. Hyatt², L. Wittenburg³, S. Rao⁴, S. McGrath⁵. ¹Colorado State University, Fort Collins, CO, USA, ²College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA, ³University of California Davis, Davis, CA, USA, ⁴Adjunct Faculty of Epidemiology, Colorado School of Public Health, University of Colorado, Denver, Fort Collins, CO, USA, ⁵Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Fort Collins, CO, USA

Our purpose was to determine the pharmacokinetics (PK) and tolerability of cannabidiol (CBD) in healthy dogs. We hypothesized oral and transdermal delivery would be well tolerated and provide measurable systemic levels of CBD.

Thirty, healthy Beagle dogs were randomly assigned to receive one of three CBD formulations (capsule, oil, or transdermal cream), twice daily for a total dose of 150 or 300 mg/day (approximately 10 and 20 mg/kg/day), over 6 weeks. Blood was collected for 12 hours following the first dose for CBD PK. At 2-, 4-, and 6-weeks, blood was collected for CBC, chemistry panel, bile acids, and CBD plasma levels. Daily observational notes and weekly physical examinations were also performed.

Pharmacokinetic analysis demonstrated that the oil formulation resulted in higher plasma concentrations and systemic exposure, with less variability. Cannabidiol exposure was dose proportional. Elimination half-life of the oil formulation following a dose of 75 and 150 mg was 199.7 ± 55.9 and 127.5 ± 32.2 minutes, respectively. Twice-daily administration maintained plasma CBD levels until study completion.

There were no significant abnormalities on CBC, urinalysis, or pre- and postprandial bile acids. Mild elevations in serum alkaline phosphatase (ALP) occurred at 4 and 6 weeks, more frequently with capsule and oil formulations at 300 mg/day. All dogs experienced diarrhea; presence, onset, and severity did not correlate with formulation or dose.

Cannabidiol appears to be well tolerated in dogs. Exposure is proportional to dose and oil formulation provides more favorable PK. These results provide a framework for future efficacy studies of CBD in dogs.

Potential Toxicity

- Large case series and isolated case reports
 - Ataxia/incoordination
 - Vomiting
 - Can be mixed toxicosis (chocolate, xylitol, etc.)
 - Rarely fatal







Laboratory Research in other species

- Analgesic
- Anti-emetic
- Anti-tumor
- Anti-inflammatory & immunomodulatory
- Modulates sleep cycle
- Diabetes
- Cardiovascular function
- Clinical Relevance???



Anecdotal Evidence





Anecdotal Evidence

- Surveys
 - Selection bias
 - cannabis company web site
 - clients of advocates
 - Dislike conventional Tx
 - Usage rates
 - Benefits
 - Adverse effects
 - Medical guidance



Quality Control

- Unregulated products often mislabeled
 - Only 17% accurately labeled
 - 60% had more THC than on label
 - Many had no detectable CBD

Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products

	Accuracy of Labeled Tetrahydrocannabinol (THC) Content						
	Accurately Labeled ^a	Underlabeled ^b	Overlabeled ^c				
Overall (3 Cities)							
Products tested, No. (%) (N = 75)	13 (17)	17 (23)	45 (60)				
Type of product, No.							
Baked goods	2	7	13				
Beverages	3	2	8				
Candy or chocolate	8	8	24				
Amount of THC, mg							
Label range	15 to 200	20 to 1000	2 to 325				
Actual range	15 to 183	34 to 1236	<1 to 267				
Deviation in THC content amount, %d							
Mean (SD)	-3 (4)	28 (13)	-47 (29)				
Maximum	9	55	-99				

Ryan Vandrey, PhD¹; Jeffrey C. Raber, PhD²; Mark E. Raber²; Brad Douglass, PhD³; Cameron Miller, MS³; Marcel O. Bonn-Miller, PhD⁴ JAMA. 2015;313(24):2491-2493. doi:10.1001/jama.2015.6613.

Quality Control

- Unregulated products often mislabeled
 - 36% had less than labeled amount CBD
 - 22% had more than labeled amount of CBD
 - Are veterinary products any better?

Table 1. Label Accuracy by Cannabidiol Extract Type									
	Cannabidiol Extract Pro								
	Oil (n = 40)	Tincture (n = 20)	Vaporization Liquid ($n = 24$)	Total (N = 84)					
Label accuracy, No. of products (%) [95% CI]									
Accurate ^a	18 (45.00) [30.71-60.17]	5 (25.00) [11.19-46.87]	3 (12.50) [4.34-31.00]	26 (30.95) [22.08-41.49]					
Under ^b	10 (25.00) [14.19-40.19]	8 (40.00) [21.88-61.34]	18 (75.00) [55.10-88.00]	36 (42.85) [32.82-53.53]					
Over ^c	12 (30.00) [18.07-45.43]	7 (35.00) [18.12-56.71]	3 (12.50) [4.34-31.00]	22 (26.19) [17.98-36.48]					

Quality Control

"Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD). As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain."

Firm	Product		Purchase Website	Product Size CBD Label Claim	Lab Results (mg/g)			Lab Results %(w/w)		
			Website		CBD	Δ9- THC	Other Cannabinoids	CBD	Δ9- THC	Other Cannabinoids
Canna Companion, LLC	Canna Companion Capsule Size: 4	WA	cannaforpets.com	4 capsules N/A CBD	1	1	CBDA: 9 THCA: 3	0.1%	0.1%	CBDA: 0.9% THCA: 0.3%
Canna-Pet, LLC	CBD Wedges - Canna-Biscuits for Dogs	WA	canna-pet.com	2oz N/A CBD	None detected above 1 mg/g			None detected above 0.1% (w/w)		
Canna-Pet, LLC	Canna-Pet for Cats	WA	canna-pet.com	14 capsules N/A CBD	5	-	_	0.5%	-	3 .
Canna-Pet, LLC	Canna-Pet MaxCBD Capsules for Dogs	WA	canna-pet.com	10 capsules N/A CBD	26	1	CBC: 1	2.6%	0.1%	CBC: 0.1%



ALL CANNABIS HARVESTED ON OR AFTER 1/1/2018 AND ALL CANNABIS PRODUCTS MANUFACTURED ON OR AFTER 1/1/2018, SHALL BE TESTED ACCORDING TO TITLE 16 OF THE CALIFORNIA CODE OF REGULATIONS, SECTION 5715, AND THE REGULATIONS THAT FOLLOW.

PHASE-IN OF REQUIRED LABORATORY TESTING	INHALABLE CANNABIS	INHALABLE CANNABIS PRODUCTS	OTHER CANNABIS & CANNABIS PRODUCTS
JANUARY 1, 2018	*		
Cannabinoids Testing	~	~	~
Moisture Content Testing	~		
Category II Residual Solvents and Processing Chemicals Testing		~	~
Category I Residual Pesticides Testing	~	~	~
Microbial Impurities Testing (A. fumigatus, A. flavus, A. niger, A. terreus)	~	~	
Microbial Impurities Testing (Escherichia coli and Salmonella spp.)	~	~	~
Homogeneity Testing of Edible Cannabis Products			~
JULY 1, 2018			
Category I Residual Solvents and Processing Chemicals Testing		~	~
Category II Residual Pesticides Testing	~	~	~
Foreign Material Testing	~	~	~
DECEMBER 31, 2018			
Terpenoids Testing	~	~	~
Mycotoxins Testing	~	~	~
Heavy Metals Testing	~	~	~
Water Activity Testing of Solid or Semi-Solid Edibles	~		~





Bureau of Cannabis Control 1625 North Market Boulevard, Suite 202-S Sacramento, CA 95834 (800) 952-5210

For the latest updates, follow the Bureau on social media







Quality Control

- Testing Regulations
 - THC/CBD content
 - Contaminates



- Basic Science
- Clinical Experience in Humans
 - Pain, nausea
- Dog/Cat lab studies
 - Basic physiology
 - Bioavailability?
 - Toxicity?

Very Promising

Limited but Promising

Limited, mixed




- Veterinary Clinical Studies
- Anecdotes
- Practical Issues
 - Laws
 - Quality Control

None (stay tuned)

Who Cares?

\$\$\$ Changing\$



 $\textbf{Idea} \to \to \textbf{Product} \to \to \textbf{Widespread Use} \to \to \textbf{Research Evidence}$

...learned a lot as a result of the FDA warning letter. We changed our verbiage in the company's marketing materials, informed the FDA and have been left alone since...We are comfortable with the gray zone.

Firm	Product	State	State Purchase Website	Product Size CBD Label	Lab Results (mg/g)			Lab Results %(w/w)		
		Website	Claim	CBD	Δ9- THC	Other Cannabinoids	CBD	Δ9- THC	Other Cannabinoids	
Canna Companion, LLC	Canna Companion Capsule Size: 4	WA	cannaforpets.com	4 capsules N/A CBD	1	1	CBDA: 9 THCA: 3	0.1%	0.1%	CBDA: 0.9% THCA: 0.3%
Canna-Pet, LLC	CBD Wedges - Canna-Biscuits for Dogs	WA	canna-pet.com	2oz N/A CBD	None detected above 1 mg/g			None detected above 0.1% (w/w)		
Canna-Pet, LLC	Canna-Pet for Cats	WA	canna-pet.com	14 capsules N/A CBD	5	===	_	0.5%	===	. >
Canna-Pet, LLC	Canna-Pet MaxCBD Capsules for Dogs	WA	canna-pet.com	10 capsules N/A CBD	26	1	CBC: 1	2.6%	0.1%	CBC: 0.1%

Unfortunately, the FDA prohibits us from discussing **any diseases or medical conditions** in conjunction with our products. We recommend you try [our] products for one month and observe the results with your own pet....We're so confident you and your pet will benefit...we offer our 100% satisfaction money-back guarantee.

All [our] products are guaranteed safe for any size pet. Canna-Pet products are **NOT** pharmaceuticals. They are organic, plant-based, non-GMO nutritional products that you can feed your pet with total confidence and ease.

CLIENT QUESTIONS

- Evidence is extremely limited
 - Safety?
 - Efficacy?
 - Better evidence coming soon!
- Probably illegal
- No reliable quality control



Don't substitute Cannabis for treatments with better evidence!!